RxDoctor Payments Data

Kalani Yamamoto, MD

Nephrology · Honolulu, HINPI 1902000532

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $310 of the $453 with a category attached, or 68.4%. 5 manufacturers reported payments, led by AstraZeneca at 54.7% of the total. That places this record below the midpoint for nephrology clinicians in HI, where the typical reported total is $2,126.

$453in general payments, 2019–2025

Across 24 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$248
  • Otsuka America Pharmaceutical, Inc.$125
  • Bayer$41
  • Vifor Pharma, Inc.$22
  • Travere Therapeutics, Inc.$18

What the payments were for

  • Food & beverage$31068%
  • Education$14332%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$453 in reported general payments places this provider in the 25th percentile of 57 nephrology providers in Hawaii.

See all nephrology providers in Hawaii

Medicare billing

Part B allowed, 2024
$286,461
Medicare patients
637
Services billed
1,916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol379$565,235
KerendiaFinerenone230$363,486
VelphoroSucroferric Oxyhydroxide77$236,562
VeltassaPatiromer Calcium Sorbitex64$88,170
JardianceEmpagliflozin48$63,937
RenvelaSevelamer Carbonate14$45,455
JanuviaSitagliptin Phosphate27$33,530
Lanthanum Carbonate44$32,561
RybelsusSemaglutide11$29,573
Sevelamer Carbonate164$28,476
InvokanaCanagliflozin11$18,038
EliquisApixaban18$16,477
Olmesartan Medoxomil96$6,902
Losartan Potassium258$6,760
Amlodipine Besylate367$6,417

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$248$565,235379 claims
BayerKerendia$41$363,486230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 57 nephrology providers in Hawaii.

Other nephrology in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →